Top 7 life sciences public investors
The top seven life sciences public investors are proving themselves to be fortunate as well as savvy in their investments. The investors managed to outperform the NASDAQ Biotechnology Index (NBI) due to their participation in some of the top biotech performers in 2014. Overall, the NBI is up 185% since November 2011 when Gilead Sciences acquired Pharmasset. Coupled with earnings upside surprises, fundamental technological leaps are pushing forward this recent biotech rally. The technology advances serving the rally include but are not limited to messenger RNA, protein folding correctors, gene therapy and exon skipping. The seven top investors are Baker Brothers Advisors, Deerfield Management, Janus Global Life Sciences Fund, OrbiMed Advisors, Perceptive Advisors, RA Capital Management and Rock Springs Capital.
